Induction of cyclooxygenase-2 protein by lipoteichoic acid from Staphylococcus aureus in human pulmonary epithelial cells

Involvement of a nuclear factor-κB-dependent pathway

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

1. This study investigated the role of protein kinase C (PKC) and transcription factor nuclear factor-κB (NF-κB) in cyclooxygenase-2 (COX-2) expression caused by lipoteichoic acid (LTA), a cell wall component of the gram-positive bacterium Staphylococcus aureus, in human pulmonary epithelial cell line (A549). 2. LTA caused dose- and time-dependent increases in COX-2 expression and COX activity, and a dose-dependent increase in PGE 2 release in A549 cells. The LTA-induced increases in COX-2 expression and COX activity were markedly inhibited by dexamethasone, actinomycin D or cyclohexamide, but not by polymyxin B, which binds and inactivates endotoxin. 3. The phosphatidylcholine-phospholipase C (PC-PLC) inhibitor (D-609) and the phosphatidate phosphohydrolase inhibitor (propranolol) reduced the LTA-induced increases in COX-2 expression and COX activity, while phosphatidylinositol-phospholipase C inhibitor (U-73122) had no effect. The PKC inhibitors (Go 6976, Ro 31-8220 and GF 109203X) and NF-κB inhibitor, pyrrolidine dithiocarbamate (PDTC), also attenuated the LTA-induced increases in COX-2 expression and COX activity. 4. Treatment of A549 cells with LTA caused an increase in PKC activity in the plasma membrane; this stimulatory effect was inhibited by D-609, propranolol, or Go 6976, but not by U-73122. 5. Exposure of A549 cells to LTA caused a translocation of p65 NF-κB from the cytosol to the nucleus and a degradation of IκB-α in the cytosol. Treatment of A549 cells with LTA caused NF-κB activation by detecting the formation of NF-κB-specific DNA-protein complex in the nucleus; this effect was inhibited by dexamethasone, D-609, propranolol, Go 6976, Ro 31-8220, or PDTC. 6. These results suggest that LTA might activate PC-PLC and phosphatidylcholine-phospholipase D to induce PKC activation, which in turn initiates NF-κB activation, and finally induces COX-2 expression and PGE 2 release in human pulmonary epithelial cell line.

Original languageEnglish
Pages (from-to)543-552
Number of pages10
JournalBritish Journal of Pharmacology
Volume134
Issue number3
Publication statusPublished - 2001

Fingerprint

Cyclooxygenase 2
Staphylococcus aureus
Epithelial Cells
Lung
Protein Kinase C
Proteins
Type C Phospholipases
Phosphatidylcholines
Propranolol
Prostaglandins E
Cytosol
Dexamethasone
Phosphatidate Phosphatase
lipoteichoic acid
Cell Line
Polymyxin B
Phospholipase D
Protein C Inhibitor
Gram-Positive Bacteria
Dactinomycin

Keywords

  • A549 cells
  • Cyclooxygenase-2
  • Lipoteichoic acid
  • NF-κB
  • Prostaglandin E
  • Protein kinase C

ASJC Scopus subject areas

  • Pharmacology

Cite this

@article{317c8fa368604e14a1dfcfc222f39eec,
title = "Induction of cyclooxygenase-2 protein by lipoteichoic acid from Staphylococcus aureus in human pulmonary epithelial cells: Involvement of a nuclear factor-κB-dependent pathway",
abstract = "1. This study investigated the role of protein kinase C (PKC) and transcription factor nuclear factor-κB (NF-κB) in cyclooxygenase-2 (COX-2) expression caused by lipoteichoic acid (LTA), a cell wall component of the gram-positive bacterium Staphylococcus aureus, in human pulmonary epithelial cell line (A549). 2. LTA caused dose- and time-dependent increases in COX-2 expression and COX activity, and a dose-dependent increase in PGE 2 release in A549 cells. The LTA-induced increases in COX-2 expression and COX activity were markedly inhibited by dexamethasone, actinomycin D or cyclohexamide, but not by polymyxin B, which binds and inactivates endotoxin. 3. The phosphatidylcholine-phospholipase C (PC-PLC) inhibitor (D-609) and the phosphatidate phosphohydrolase inhibitor (propranolol) reduced the LTA-induced increases in COX-2 expression and COX activity, while phosphatidylinositol-phospholipase C inhibitor (U-73122) had no effect. The PKC inhibitors (Go 6976, Ro 31-8220 and GF 109203X) and NF-κB inhibitor, pyrrolidine dithiocarbamate (PDTC), also attenuated the LTA-induced increases in COX-2 expression and COX activity. 4. Treatment of A549 cells with LTA caused an increase in PKC activity in the plasma membrane; this stimulatory effect was inhibited by D-609, propranolol, or Go 6976, but not by U-73122. 5. Exposure of A549 cells to LTA caused a translocation of p65 NF-κB from the cytosol to the nucleus and a degradation of IκB-α in the cytosol. Treatment of A549 cells with LTA caused NF-κB activation by detecting the formation of NF-κB-specific DNA-protein complex in the nucleus; this effect was inhibited by dexamethasone, D-609, propranolol, Go 6976, Ro 31-8220, or PDTC. 6. These results suggest that LTA might activate PC-PLC and phosphatidylcholine-phospholipase D to induce PKC activation, which in turn initiates NF-κB activation, and finally induces COX-2 expression and PGE 2 release in human pulmonary epithelial cell line.",
keywords = "A549 cells, Cyclooxygenase-2, Lipoteichoic acid, NF-κB, Prostaglandin E, Protein kinase C",
author = "Chien-Huang Lin and Kuan, {I. Hui} and Lee, {Horng Mo} and Lee, {Wen Sen} and Sheu, {Joen Rong} and Ho, {Yuan Soon} and Wang, {Chun Hua} and Kuo, {Han Pin}",
year = "2001",
language = "English",
volume = "134",
pages = "543--552",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Induction of cyclooxygenase-2 protein by lipoteichoic acid from Staphylococcus aureus in human pulmonary epithelial cells

T2 - Involvement of a nuclear factor-κB-dependent pathway

AU - Lin, Chien-Huang

AU - Kuan, I. Hui

AU - Lee, Horng Mo

AU - Lee, Wen Sen

AU - Sheu, Joen Rong

AU - Ho, Yuan Soon

AU - Wang, Chun Hua

AU - Kuo, Han Pin

PY - 2001

Y1 - 2001

N2 - 1. This study investigated the role of protein kinase C (PKC) and transcription factor nuclear factor-κB (NF-κB) in cyclooxygenase-2 (COX-2) expression caused by lipoteichoic acid (LTA), a cell wall component of the gram-positive bacterium Staphylococcus aureus, in human pulmonary epithelial cell line (A549). 2. LTA caused dose- and time-dependent increases in COX-2 expression and COX activity, and a dose-dependent increase in PGE 2 release in A549 cells. The LTA-induced increases in COX-2 expression and COX activity were markedly inhibited by dexamethasone, actinomycin D or cyclohexamide, but not by polymyxin B, which binds and inactivates endotoxin. 3. The phosphatidylcholine-phospholipase C (PC-PLC) inhibitor (D-609) and the phosphatidate phosphohydrolase inhibitor (propranolol) reduced the LTA-induced increases in COX-2 expression and COX activity, while phosphatidylinositol-phospholipase C inhibitor (U-73122) had no effect. The PKC inhibitors (Go 6976, Ro 31-8220 and GF 109203X) and NF-κB inhibitor, pyrrolidine dithiocarbamate (PDTC), also attenuated the LTA-induced increases in COX-2 expression and COX activity. 4. Treatment of A549 cells with LTA caused an increase in PKC activity in the plasma membrane; this stimulatory effect was inhibited by D-609, propranolol, or Go 6976, but not by U-73122. 5. Exposure of A549 cells to LTA caused a translocation of p65 NF-κB from the cytosol to the nucleus and a degradation of IκB-α in the cytosol. Treatment of A549 cells with LTA caused NF-κB activation by detecting the formation of NF-κB-specific DNA-protein complex in the nucleus; this effect was inhibited by dexamethasone, D-609, propranolol, Go 6976, Ro 31-8220, or PDTC. 6. These results suggest that LTA might activate PC-PLC and phosphatidylcholine-phospholipase D to induce PKC activation, which in turn initiates NF-κB activation, and finally induces COX-2 expression and PGE 2 release in human pulmonary epithelial cell line.

AB - 1. This study investigated the role of protein kinase C (PKC) and transcription factor nuclear factor-κB (NF-κB) in cyclooxygenase-2 (COX-2) expression caused by lipoteichoic acid (LTA), a cell wall component of the gram-positive bacterium Staphylococcus aureus, in human pulmonary epithelial cell line (A549). 2. LTA caused dose- and time-dependent increases in COX-2 expression and COX activity, and a dose-dependent increase in PGE 2 release in A549 cells. The LTA-induced increases in COX-2 expression and COX activity were markedly inhibited by dexamethasone, actinomycin D or cyclohexamide, but not by polymyxin B, which binds and inactivates endotoxin. 3. The phosphatidylcholine-phospholipase C (PC-PLC) inhibitor (D-609) and the phosphatidate phosphohydrolase inhibitor (propranolol) reduced the LTA-induced increases in COX-2 expression and COX activity, while phosphatidylinositol-phospholipase C inhibitor (U-73122) had no effect. The PKC inhibitors (Go 6976, Ro 31-8220 and GF 109203X) and NF-κB inhibitor, pyrrolidine dithiocarbamate (PDTC), also attenuated the LTA-induced increases in COX-2 expression and COX activity. 4. Treatment of A549 cells with LTA caused an increase in PKC activity in the plasma membrane; this stimulatory effect was inhibited by D-609, propranolol, or Go 6976, but not by U-73122. 5. Exposure of A549 cells to LTA caused a translocation of p65 NF-κB from the cytosol to the nucleus and a degradation of IκB-α in the cytosol. Treatment of A549 cells with LTA caused NF-κB activation by detecting the formation of NF-κB-specific DNA-protein complex in the nucleus; this effect was inhibited by dexamethasone, D-609, propranolol, Go 6976, Ro 31-8220, or PDTC. 6. These results suggest that LTA might activate PC-PLC and phosphatidylcholine-phospholipase D to induce PKC activation, which in turn initiates NF-κB activation, and finally induces COX-2 expression and PGE 2 release in human pulmonary epithelial cell line.

KW - A549 cells

KW - Cyclooxygenase-2

KW - Lipoteichoic acid

KW - NF-κB

KW - Prostaglandin E

KW - Protein kinase C

UR - http://www.scopus.com/inward/record.url?scp=0034779037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034779037&partnerID=8YFLogxK

M3 - Article

VL - 134

SP - 543

EP - 552

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 3

ER -